CEO Q&A with Neil Crabb at Frontier IP Group Plc (LON:FIPP)

Frontier IP Group Plc (LON:FIPP) Chief Executive Officer Neil Crabb caught up with DirectorsTalk for an exclusive interview to discuss their partnership with the Department for International Trade, progress in Portugal, why they chose Portugal and future updates for their portfolio companies.

 

Q1: Neil, you published an announcement yesterday, can you just remind us what that was?

A1: Frontier IP Group has entered into a partnership with the Department for International Trade which really is going to help us build on the position that we’ve established in Portugal, we’ve been working with them for some time, but this is an extension of that relationship.

It means that the British Embassy in Lisbon will provide us with strategic support so with regular meetings with the Ambassador and the staff at the Department for International Trade and that introductions will be made to potential industry partners and key decision makers in the Portuguese government and economy.

So, from our point of view, this is obviously a prestigious endorsement from the UK government and it’s really important that we’re seen to be keeping the right company so it’s strengthening our presence in the market and it really should help to support the IP commercialisation work that we’re doing.

 

Q2: What stage are you at in Portugal?

A2: We’ve been working in Portugal for 2.5 years, we’ve got two formal university relationships, that have already been announced, with the Universidade de Nova de Lisboa in Lisbon and with the Universidade de Evora.

We’ve also built a strong relationship with the Embassy, we had a Capital Markets Day there, at the Ambassador’s residence last January and we had over 70 people ranging from investors to academics to people from the business community therein attending. We were also able there to show working demonstrations of a number of Portuguese technologies including paper-based sensors, one actually from the UK, an energy efficient micro-inverter and many others.

So, things are progressing really well, we’re in discussions with several other Portuguese universities where relationships have not yet been announced but importantly, we will shortly be announcing our first actual spin-out company very shortly.

 

Q3: Why Portugal?

A3: Well, as far as we know there’s no other company similar to ours that’s operating there so there’s a clear opportunity for us to add value to what we see as very strong research base and where there is increasing pressure for commercialisation.

So, what a lot of people don’t realise about Portugal is that there are actually a number of world-leading companies there already so by example, the world’s biggest cork company, the third largest paper company and one of the leaders in renewables, all Portuguese companies. We’re really interested when we see that strong industrial base because it means there’s a lot of us to go at and where you see strong industrial players, very often that also maps to a strong research base as well.

 

Q4: And as for the rest of Frontier IP Group?

A4: Both us and our portfolio companies continue to make really good commercial progress. Alusid, as we’ve already said, is close to completing its fundraising and is in the proves of scaling up. Nandi and Fieldwork Robotics are in detailed discussions with potential industry partners and that’s very positive.

So, we’re hoping we’ll see more good news coming out that we’ll be able to share with you very soon in the future.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Frontier IP Group Plc

    More articles like this

    Frontier IP Group Plc

    Animal Lovers and Zoonotic Diseases: 5 Things to Know

    Zoonotic diseases, or zoonoses, are on the rise. That may first bring to mind exotic diseases like Ebola, but the reality is that many zoonotic infections happen closer to home, often during everyday activities. In 2018,

    Frontier IP Group Plc

    AI-based initiatives catalyzing immunotherapy in 2018

    Artificial intelligence (AI) has been dynamically changing the field of drug discovery in several areas, including immunotherapy, oncotherapy, neurological disease, and many more. Described here is an ensemble of the initiatives in place to advance the field of

    Frontier IP Group Plc

    Frontier IP Group Plc appoint N+1 Singer as sole broker

    Frontier IP Group PLC (LON:FIPP), a specialist in commercialising university intellectual property, today announced the appointment of Nplus1 Singer Advisory LLP as the Group’s sole broker with immediate effect. Allenby Capital Limited remains the Group’s Nominated Adviser.

    Frontier IP Group Plc

    Britain’s university spinout sector is thriving

    They are among Britain’s greatest national treasures and a powerful engine of ideas and innovation for the nation’s booming technology industry. But how good are UK universities at commercialising the research and expertise which springs from

    Frontier IP Group Plc

    Exscientia CEO explains how AI is transforming drug discovery

    In recent decades a strange confluence has formed in the pharmaceutical industry. A range of powerful technologies have brought enormous new capabilities to the sector, productivity has been simultaneously declining. Deloitte’s Centre for Health Solutions estimates that projected returns on investment

    Frontier IP Group Plc

    How technology is revolutionising the healthcare industry

    A technology revolution is transforming the healthcare industry, changing everything from how patients are diagnosed and treated to our battle against some of the world’s most serious diseases. It’s a revolution fuelled by new sources of

    Frontier IP Group Plc

    Artificial Intelligence will Revolutionise Drug Discovery

    New technologies are making their way into the healthcare industry and healthcare providers are already experimenting with advances such as smart pill technology, 3D-printed medication, and mobile apps. But probably the biggest potential lies in artificial intelligence

    Frontier IP Group Plc

    Rallybio forges joint venture with U.K. tech firm

    A Farmington biotech startup formed by a trio of former top Alexion executives said it is working on drug discovery with an artificial intelligence company in the United Kingdom. Rallybio, focused on rare diseases, has not yet publicly

    Frontier IP Group Plc

    What is leptospirosis and how can it harm us and our pets?

    Recently reported cases of the often fatal bacterial infection leptospirosis in dogs in Sydney have raised the issue of animal diseases that also affect humans. This zoonotic disease is spread by rats and other rodents. However, this

    Frontier IP Group Plc

    The Robot Uprising Is Here

    The robot uprising is inevitable. Take the world’s first raspberry-picking robot, an autonomous machine that’s in development by Fieldwork Robotics at the University of Plymouth in the UK. This fruit-picking Terminator, so to speak, was developed for

    Frontier IP Group Plc

    The UK’s 50 Most Disruptive Companies Revealed

    After receiving applications from a wide range of early stage and more established companies from across industries, the initial list was whittled down to 100 by D/SRUPTION. The list was then submitted to an expert judging

    Frontier IP Group Plc

    Artificial intelligence in the world of drug discovery

    Charlotte Walker-Osborn, a Partner and Head of Technology Sector (International) at global law-firm Eversheds Sutherland and a legal expert in technology law, explains some of the challenges and potential future of artificial intelligence (AI) in the

    Frontier IP Group Plc

    11 diseases which can cause infection

    Illnesses that can pass from animals to humans are known as zoonotic. They’re surprisingly common: More than six out of every 10 known infectious diseases in people are actually contracted from animals, according to the CDC.